In This Article:
We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Palvella Therapeutics, Inc. (NASDAQ:PVLA) stands against the other biotech stocks.
No matter the market environment, you’ll always find entertainment in the biotech space. There will always be biotech stocks making huge swings in both directions and these stocks can make or break your portfolio in a very small amount of time due to the nature of how important clinical trial results are for these companies.
The United Nations forecasts that the over-65 age group will grow by 150% from 800 million in 2024 to 2 billion by 2067. This "older, richer & sicker" population is expected to push global healthcare spending on medicines up 12% to $2.3 trillion by 2028. If you combine that with AI making breakthroughs in healthcare more frequent, you’ll see many more biotech stocks starting to pop to the upside over the coming years.
Methodology
For this article, I screened the top-performing biotech stocks year-to-date.
I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A biopharmaceutical scientist in a lab examining a vial of pharmaceuticals.
Palvella Therapeutics, Inc. (NASDAQ:PVLA)
Number of Hedge Fund Holders In Q4 2024: 9
Palvella Therapeutics, Inc. (NASDAQ:PVLA) is a clinical-stage biopharmaceutical company that makes therapies for rare genetic skin diseases with no FDA-approved therapies.
The stock is up significantly so far in 2025 after Palvella Therapeutics, Inc. (NASDAQ:PVLA)'s announcement on February 10, 2025, that it would expand its Phase 3 SELVA clinical trial of QTORIN™ rapamycin for microcystic lymphatic malformations to include younger pediatric patients aged 3 to 5 years old.
Before that, Palvella Therapeutics, Inc. (NASDAQ:PVLA) announced the publication of results from its Phase 2 clinical trial of QTORIN™ rapamycin for microcystic lymphatic malformations in the Journal of Vascular Anomalies, reporting that 100% of participants were either "Much Improved" or "Very Much Improved" as rated by the Clinician Global Impression of Change.